Cargando…

The Human TOR Signaling Regulator Is the Key Indicator of Liver Cancer Patients’ Overall Survival: TIPRL/LC3/CD133/CD44 as Potential Biomarkers for Early Liver Cancers

SIMPLE SUMMARY: We recently reported that the human TOR signaling regulator (hereafter TIPRL) contributes to the drug-resistance of hepatocellular carcinomas (HCCs) and the involvement of TIPRL/LC3/CD133 in liver cancer aggressiveness. This study aims to determine prognostic and diagnostic efficacie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jun, Soo Young, Yoon, Hyang Ran, Yoon, Ji-Yong, Jeon, Su-Jin, Lee, Jeong-Ju, Halder, Debasish, Kim, Jin-Man, Kim, Nam-Soon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230774/ https://www.ncbi.nlm.nih.gov/pubmed/34208132 http://dx.doi.org/10.3390/cancers13122925

Ejemplares similares

The positive correlation of TIPRL with LC3 and CD133 contributes to cancer aggressiveness: potential biomarkers for early liver cancer
por: Jun, Soo Young, et al.
Publicado: (2019)

TIPRL potentiates survival of lung cancer by inducing autophagy through the eIF2α-ATF4 pathway
por: Jeon, Su-Jin, et al.
Publicado: (2019)

Prognostic value of CD133(+) CD54(+) CD44(+) circulating tumor cells in colorectal cancer with liver metastasis
por: Fang, Chao, et al.
Publicado: (2017)

CD133(+)CD54(+)CD44(+) circulating tumor cells as a biomarker of treatment selection and liver metastasis in patients with colorectal cancer
por: Fang, Chao, et al.
Publicado: (2016)

Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer
por: WANG, CHUNXIA, et al.
Publicado: (2012)

The Potential Role of CD44 and CD133 in Colorectal Stem Cell Cancer
por: Abdou Hassan, Wael, et al.
Publicado: (2022)

Systems approach to characterize the metabolism of liver cancer stem cells expressing CD133
por: Hur, Wonhee, et al.
Publicado: (2017)

Evaluation of CD44 and CD133 as markers of liver cancer stem cells in Egyptian patients with HCV-induced chronic liver diseases versus hepatocellular carcinoma
por: Rozeik, Mohammed Saeed, et al.
Publicado: (2017)

Role of CD44(high)/CD133(high) HCT-116 cells in the tumorigenesis of colon cancer
por: Zhou, Jin-Yong, et al.
Publicado: (2016)

Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma
por: Nosrati, Anahita, et al.
Publicado: (2014)

Expression of the Cancer Stem Cell Markers CD44 and CD133 in Colorectal Cancer: An Immunohistochemical Staining Analysis
por: Hong, Injae, et al.
Publicado: (2015)

CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure
por: Tsunekuni, Kenta, et al.
Publicado: (2019)

Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation
por: Hong, Sung Woo, et al.
Publicado: (2016)

Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer
por: Chen, Wei-Ching, et al.
Publicado: (2015)

Cobalt ferrite nanoparticle for the elimination of CD133+CD44(+) and CD44(+)CD24(−), in breast and skin cancer stem cells, using non-ionizing treatments
por: Khalili Najafabad, Bahareh, et al.
Publicado: (2023)

CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy
por: Li, Jian, et al.
Publicado: (2016)

Immunohistochemical Detection of Cancer Stem Cell Related Markers CD44 and CD133 in Metastatic Colorectal Cancer Patients
por: Pitule, Pavel, et al.
Publicado: (2014)

Knockdown of 14-3-3ζ enhances radiosensitivity and radio-induced apoptosis in CD133(+) liver cancer stem cells
por: Lee, Young Ki, et al.
Publicado: (2014)

Brca1 breast tumors contain distinct CD44(+)/CD24(- )and CD133(+ )cells with cancer stem cell characteristics
por: Wright, Mollie H, et al.
Publicado: (2008)

Potential Role of CD133 Expression in the Susceptibility of Human Liver Cancer Stem-Like Cells to TRAIL
por: Lee, Su-Hoon, et al.
Publicado: (2016)

Evaluation of Cancer Stem Cell Markers CD133, CD44, CD24: Association with AKT Isoforms and Radiation Resistance in Colon Cancer Cells
por: Sahlberg, Sara Häggblad, et al.
Publicado: (2014)

Effects of flavopiridol on critical regulation pathways of CD133(high)/CD44(high) lung cancer stem cells
por: Bozok Cetintas, Vildan, et al.
Publicado: (2016)

Isolation of CD133+ Liver Stem Cells for Clonal Expansion
por: Rountree, C. Bart, et al.
Publicado: (2011)

Label-free quantitative proteomics of CD133-positive liver cancer stem cells
por: Tsai, Sheng-Ta, et al.
Publicado: (2012)

Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme
por: Brown, Daniel V., et al.
Publicado: (2015)

Clinicopathological significance of CD133 and CD44 expression in infiltrating ductal carcinoma and their relationship to angiogenesis
por: Han, Zhengquan, et al.
Publicado: (2015)

Transient mTOR Inhibition Facilitates Continuous Growth of Liver Tumors by Modulating the Maintenance of CD133+ Cell Populations
por: Yang, Zhaojuan, et al.
Publicado: (2011)

Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis
por: Durko, L., et al.
Publicado: (2017)

Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer
por: Lugli, A, et al.
Publicado: (2010)

Oxytetracycline have the therapeutic efficiency in CD133(+) HCC population through suppression CD133 expression by decreasing of protein stability of CD133
por: Song, Yeonhwa, et al.
Publicado: (2018)

Induced growth inhibition, cell cycle arrest and apoptosis in CD133(+)/CD44(+) prostate cancer stem cells by flavopiridol
por: SONER, BURAK CEM, et al.
Publicado: (2014)

Corrigendum to “Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis”
por: Durko, L., et al.
Publicado: (2017)

TIPRL, a Novel Tumor Suppressor, Suppresses Cell Migration, and Invasion Through Regulating AMPK/mTOR Signaling Pathway in Gastric Cancer
por: Luan, Meng, et al.
Publicado: (2020)

Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells
por: Friel, Anne M, et al.
Publicado: (2010)

Juglone and KPT6566 Suppress the Tumorigenic Potential of CD44(+)CD133(+) Tumor-Initiating Caco-2 Cells In Vitro and In Vivo
por: Kim, Junghoon, et al.
Publicado: (2022)

Downregulation of CD44 reduces doxorubicin resistance of CD44(+)CD24(−) breast cancer cells
por: Van Phuc, Pham, et al.
Publicado: (2011)

Identification and characterization of CD133(+)CD44(+) cancer stem cells from human laryngeal squamous cell carcinoma cell lines
por: Wang, Jue, et al.
Publicado: (2017)

Dual-targeting nanomicelles with CD133 and CD44 aptamers for enhanced delivery of gefitinib to two populations of lung cancer-initiating cells
por: Huang, Xiaolong, et al.
Publicado: (2020)

Single-cell sequencing reveals CD133(+)CD44(−)-originating evolution and novel stemness related variants in human colorectal cancer
por: Zhang, Xiaoyan, et al.
Publicado: (2022)

Gliomasphere marker combinatorics: multidimensional flow cytometry detects CD44+/CD133+/ITGA6+/CD36+ signature
por: Erhart, Friedrich, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_epqp46o9cjco6jepdop8fej5iv